Compare KeyCorp (KEY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Novo Nordisk A/S — how do they compare? KeyCorp trades at $19.97 (market cap $21.45B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 7.7× KeyCorp's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Novo Nordisk A/S for 116 Days on average.
| KEY | NVO | |
|---|---|---|
Market Cap | $21.45B | $165.31B |
Volume | 19,450,846 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $23.99 | $63.98 |
52-Week Low | $16.78 | $35.29 |
Typical Hold Time | 66 Days | 116 Days |
Enterprise Value | $34.63B | $179.56B |
Dividend Yield | 4.08% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $20.1, up 1.36% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly EPS beats. Recent news includes a prime rate hike to 7.00% and executive appointments, while the dividend remains frozen.
The outlook is mixed: analyst consensus is bullish with a $25.00 price target, but technical weakness and competitive dividend pressures pose risks. Revenue growth and share buybacks support upside, yet interest rate sensitivity and margin pressures require monitoring for sustained performance.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
